Clinical Trial Update: Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating hepatic arterial infusion combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED